Loading…

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature

The development of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of patients with advanced stage cancers. However, immune-related adverse events are frequently observed. Cardiac toxicity from ICI therapy can range from asymptomatic troponin-I elevations to conduction abnormali...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in oncology 2019-01, Vol.12 (1), p.260-276
Main Authors: Agrawal, Nikhil, Khunger, Arjun, Vachhani, Pankit, Colvin, Teresa A., Hattoum, Alexander, Spangenthal, Edward, Curtis, Anne B., Dy, Grace K., Ernstoff, Marc S., Puzanov, Igor
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The development of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of patients with advanced stage cancers. However, immune-related adverse events are frequently observed. Cardiac toxicity from ICI therapy can range from asymptomatic troponin-I elevations to conduction abnormalities of the heart and even fulminant myocarditis. Although rare, myocarditis is a potentially fatal adverse effect of ICI therapy. We present a series of five cases of ICI-related cardio-toxicity diagnosed and managed at Roswell Park Comprehensive Cancer Center along with a review of published case reports in the literature. Our series highlights the importance of high clinical suspicion, early diagnosis of myocarditis, and prompt initiation of immunosuppressive therapy.
ISSN:1662-6575
1662-6575
DOI:10.1159/000498985